General immune dampening is associated with disturbed metabolism at diagnosis of type 1 diabetes

Rydén, Anna; Ludvigsson, Johnny; Fredrikson, Mats; Faresjö, Maria

doi:10.1038/pr.2013.167

Cited by 11 publications

(11 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL‐13, similar to IL‐4, suppresses the ongoing β‐cell destruction and prevents T1D development. IL‐13 production is decreased in patients with T1D, even in subjects carrying a genetic risk of T1D, compared with that in healthy control subjects . Importantly, the defective IL‐13 production correlates with the reduced regulatory capacity of iNKT cells, implying that IL‐13 secretion is important for the regulatory role of iNKT cells in T1D .…”

Section: Classical Cytokines With Anti‐inflammatory Rolessupporting

confidence: 55%

“…IL-13 production is decreased in patients with T1D, even in subjects carrying a genetic risk of T1D, compared with that in healthy control subjects. 28,29 Importantly, the defective IL-13 production correlates with the reduced regulatory capacity of iNKT cells, implying that IL-13 secretion is important for the regulatory role of iNKT cells in T1D. 30 Consistent with these findings, treatment with a recombinant human IL-13 markedly delays the progression of insulitis and diminishes the incidence of spontaneous diabetes.…”

Section: Type-2 Cytokinesmentioning

confidence: 75%

See 1 more Smart Citation

Cytokines in type 1 diabetes: mechanisms of action and immunotherapeutic targets

Lü

Liu

et al. 2020

Clin & Trans Imm

View full text Add to dashboard Cite

Cytokines play crucial roles in orchestrating complex multicellular interactions between pancreatic β cells and immune cells in the development of type 1 diabetes (T1D) and are thus potential immunotherapeutic targets for this disorder. Cytokines that can induce regulatory functions—for example, IL‐10, TGF‐β and IL‐33—are thought to restore immune tolerance and prevent β‐cell damage. By contrast, cytokines such as IL‐6, IL‐17, IL‐21 and TNF, which promote the differentiation and function of diabetogenic immune cells, are thought to lead to T1D onset and progression. However, targeting these dysregulated cytokine networks does not always result in consistent effects because anti‐inflammatory or proinflammatory functions of cytokines, responsible for β‐cell destruction, are context dependent. In this review, we summarise the current knowledge on the involvement of well‐known cytokines in both the initiation and destruction phases of T1D and discuss advances in recently discovered roles of cytokines. Additionally, we emphasise the complexity and implications of cytokine modulation therapy and discuss the ways in which this strategy has been translated into clinical trials.

show abstract

Section: Classical Cytokines With Anti‐inflammatory Rolessupporting

confidence: 55%

Section: Type-2 Cytokinesmentioning

confidence: 75%

Cytokines in type 1 diabetes: mechanisms of action and immunotherapeutic targets

Lü

Liu

et al. 2020

Clin & Trans Imm

View full text Add to dashboard Cite

show abstract

“…Our study used acute T1D mice that presented only a modest increase in Th1 cytokine secretion at 72h post alloxan injection. The decrease in BALF and serum cytokines in diabetic mice compared to non-diabetic post-challenge with Ova may be attributed to a general dampening of spontaneous cytokine secretions observed at diagnosis of T1D in children (Rydén et al, 2014).…”

Section: Discussionmentioning

confidence: 94%

Role of Dexamethasone on immune dysregulation mediated through Th1/Th2 cytokine balance in mice challenged with type 1 diabetes and allergic asthma

Ravikumar

2019

ijrps

View full text Add to dashboard Cite

Dysregulated equilibrium between T helper 1 (Th1) and T helper 2 (Th2) immune responses has been implicated in the pathogenesis of type 1 diabetes (T1D) and asthma. Conflicting evidence exist explaining the association between T1D and asthma and is still a point of debate. In the present study, our objective was to investigate the influence of associated T1Dco morbid condition on the induction of experimental asthma in mice and also to evaluate the efficacy of Dexamethasone (0.5 mg/kg, s.c.ly) in these mice. Type 1 diabetes was induced by a single intravenous injection of alloxan (80 mg/kg) in Balb/c mice. Following diabetes induction, mice were sensitized with an intraperitoneal injection of 50 µg ovalbumin (Ova) emulsified in 2.5 mg aluminum hydroxide on days 3 and 8. From day 13 to day 15, animals were challenged intranasally with 100 µg Ova in 25 µl of sterile saline. Dexamethasone treatment was initiated on sensitization day and continued once in 2 days thereafter until day 15. Control animals received only saline without Ova. On day 16, mice were subjected to nasal hyperresponsiveness (NHR) immediately after the Ova challenge. Bronchioalveolar lavage fluid (BALF), blood, and lungs were collected 1h post completion of NHR for further analysis. Alloxan diabetic mice showed significantly lower levels of eosinophils in BALF and blood with the corresponding decrease in inflammatory cells around airways in hematoxylin & eosin-stained lung sections, but with no change in NHR than in non-diabetics after Ova sensitization and challenge. Dexamethasone treatment showed a significant reduction of airway inflammation and related Th2 immune responses, with a lesser magnitude of efficacy in diabetic asthma mice than in non-diabetic asthma mice. The presence of T1D featured a unique, yet the intermediary stage of asthma induction and also presented an altered magnitude of Dexamethasone efficacy compared to the absence of T1D in the murine model of Ova induced asthma.

show abstract

“…Although destruction of beta cells is believed to be permanent, in recent studies beta cells including insulin were observed in pancreatic autopsy samples obtained from patients with T1D and increased C-peptide secretion after meal stimulus were reported [1,2]. Herein, we present a case with increased fasting and mixed-meal stimulated C-peptide levels, 10 years after the diagnosis of T1D.…”

Section: Introductionmentioning

confidence: 88%

“…The decrease in β-cell function in type 1 diabetic patients varies from patient to patient [1]. Increased endogenous insulin production in patients with type 1 diabetes can improve glycemic control and decrease the complication and mortality rates.…”

Section: Introductionmentioning

confidence: 99%

Increased fasting and stimulated c- peptide levels after the diagnosis of type 1 diabetes: a case report

Tamer¹,

Çaklılı²,

Kartal³

et al. 2017

Integr Obesity Diabetes

View full text Add to dashboard Cite

General immune dampening is associated with disturbed metabolism at diagnosis of type 1 diabetes

Cited by 11 publications

References 33 publications

Cytokines in type 1 diabetes: mechanisms of action and immunotherapeutic targets

Cytokines in type 1 diabetes: mechanisms of action and immunotherapeutic targets

Role of Dexamethasone on immune dysregulation mediated through Th1/Th2 cytokine balance in mice challenged with type 1 diabetes and allergic asthma

Increased fasting and stimulated c- peptide levels after the diagnosis of type 1 diabetes: a case report

Contact Info

Product

Resources

About